No Magic Pill Will Provide All Erectile Dysfunction Treatment

Erectile Dysfunction Treatment
Medications are not quite a magic pill to improve the sex lives of men with erectile dysfunction problems, a Deakin University study has found.
Hayley Matic conducted the study for her Doctor of Psychology (Health) with Deakin's School of Psychology under the supervision of Professor Marita McCabe. She found that while oral medications, known as PDE5 inhibitors, may restore a man's 'sexual function' they don't necessarily restore a man's 'sexual health'.
"As well as the obvious physiological aspects, men with erectile dysfunction (ED) suffer a range of problems such as significantly poorer self esteem, sense of masculinity, sexual satisfaction and relationship satisfaction," Dr Matic said.
"This study found that overall well being was not improved in the men who had used medical interventions for their erectile dysfunction."
Dr Matic's study explored the psychological and relationship impact of� � erectile dysfunction on the lives of Australian men and their partners. It also looked at men's help-seeking behaviour and experiences with oral medication as treatments for their ED. It involved 410 men with� � erectile dysfunction and 242 men without ED.
"Erectile dysfunction affects up to 50 per cent of men at some point in their lives and is generally treated with the use of oral medications," Dr Matic said.
"The focus on the medical and biological elements of� � erectile dysfunction has led to a relative dismissal of the role of psychological and relationship aspects of men's sexual experiences. As a result many men stop using the medications and continue to suffer ED as well as the associated problems with their masculinity, self-esteem and quality of life.
"Hopefully the results of this study will open up current mainstream treatments for this sexual dysfunction to include greater awareness of the psychological and relationship factors inherent in a man's sexual health."
Dr Matic suggests that improvements could come from:

• Ensuring GPs and specialists who assess and treat sexual dysfunction are educated in the potential broad ranging impact of� � erectile dysfunction on a man's life

• Ensuring that those prescribing� � erectile dysfunction medications are able to talk to their patients about their expectations for the use of the drugs

• Increased development of and referral to non-medical treatments for erectile dysfunction, either in conjunction with medication treatment or as a stand-alone

• Increased inclusion of a man's partner in the assessment and treatment for� � erectile dysfunction in both medical and other settings.
  

"As medications are only potentially able to address the biological/physiological aspects of sexual arousal, there is a clear need to consider broader application of a biopsychosocial model of health to our understanding and treatment of erectile dysfunction," Dr Matic said.

Possible Link between Erectile Dysfunction Drugs and Optic Neuropathy

Erectile Dysfunction and Impotence Drug Alert

FDA is alerting healthcare practitioners about a possible association between PDE-5 inhibitors used to treat erectile dysfunction, such as Viagra, Levitra and Cialis, and a serious vision disorder. This condition, known as NAION, or non-arteritic ischemic optic neuropathy, can cause a sudden loss of eyesight by blocking blood flow to the optic nerve. This possible association is reflected in newly approved labeling for these drugs. Thus far, over 40 cases of NAION have been reported in patients using the drugs, and 26 of these patients experienced continuing or permanent vision loss.
Though the proportion of patients affected is probably very small, since NAION can produce permanent vision loss, it's important for physicians and patients to be aware of the possible risk. Moreover, we do not know for sure that these drugs were responsible for the vision problems. It could be the drugs or it could be certain other known risk factors like diabetes, smoking, hyperlipidemia, hypertension - but in about half of the reported cases, there was a temporal relationship between taking the drug and the onset of visual symptoms, and that does raise some concern about the role of the drugs.
Practitioners should caution patients who are taking these drugs that if they experience a sudden loss of vision in one or both eyes, to immediately stop the medication and seek medical attention. Practitioners should also ask patients whether they've ever experienced severe loss of vision, which might indicate that they've had a prior episode of NAION. These patients are at increased risk of developing the condition again.